International Biotechnology (LON:IBT - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 686.23 ($8.57) and traded as high as GBX 710 ($8.87). International Biotechnology shares last traded at GBX 710 ($8.87), with a volume of 48,839 shares.
International Biotechnology Stock Up 0.8 %
The company has a market capitalization of £264.63 million, a price-to-earnings ratio of 1,491.67 and a beta of 0.21. The company has a current ratio of 0.46, a quick ratio of 0.32 and a debt-to-equity ratio of 9.66. The firm's 50 day simple moving average is GBX 693.87 and its 200-day simple moving average is GBX 686.65.
International Biotechnology (LON:IBT - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported GBX (9.16) (($0.11)) earnings per share (EPS) for the quarter. International Biotechnology had a return on equity of 6.25% and a net margin of 75.33%. On average, sell-side analysts anticipate that International Biotechnology will post 0.9435943 EPS for the current fiscal year.
International Biotechnology Increases Dividend
The business also recently announced a dividend, which will be paid on Friday, January 24th. Shareholders of record on Thursday, December 19th will be issued a GBX 15.56 ($0.19) dividend. The ex-dividend date is Thursday, December 19th. This is a boost from International Biotechnology's previous dividend of $14.50. This represents a yield of 2.21%. International Biotechnology's dividend payout ratio (DPR) is 6,041.67%.
Insider Buying and Selling
In other International Biotechnology news, insider Katherine Cornish-Bowden acquired 1,500 shares of the stock in a transaction that occurred on Tuesday, December 17th. The shares were purchased at an average cost of GBX 713 ($8.90) per share, with a total value of £10,695 ($13,353.73). Insiders own 4.18% of the company's stock.
About International Biotechnology
(
Get Free Report)
The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.
The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
Featured Stories
Before you consider International Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and International Biotechnology wasn't on the list.
While International Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
